EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome

Deepa J Arachchillage iD, Mike Laffan, Charis Pericleous

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24021331 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Deepa J Arachchillage und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London W12 0NN, UK. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Antimalarials, Thrombosis. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Versus Arthritis, Medical Research Council, MRC UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiphospholipid syndrome (APS) is an acquired highly prothrombotic disorder in which thrombo-inflammatory antiphospholipid antibodies (aPL) cause thrombosis via multiple mechanisms, including endothelial damage and activation. Obstetric complications in APS are caused by placental thrombosis, inflammation and complement activation. Anticoagulation is poorly effective in some patients especially those with triple positive aPL who are at ~30% risk of thrombosis recurrence within 10 years. Increasing therapeutic anticoagulation intensity may be beneficial but leads to excess bleeding with serious complications, such as intracerebral haemorrhage. Nonetheless, anticoagulation is still the mainstay of treatment despite the autoimmune nature of APS. The antimalarial immunomodulatory drug hydroxychloroquine (HCQ) has been used for many years for the treatment of inflammatory rheumatic diseases. HCQ has complex pleiotropic mechanisms of action upon multiple cell types. The proposed biological processes that HCQ regulates support the hypothesis that it may be a successful adjunctive treatment in the prevention of recurrent thrombosis and pregnancy complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid SyndromeAntimalarialsThrombosisHumansFemalePregnancyHydroxychloroquineFibrinolytic AgentsPlacentaAnticoagulants

Stichwörter der Autor:innen

antiphospholipid syndromehydroxychloroquineinflammationpregnancy complicationsthrombosis

Substanzen

HydroxychloroquineFibrinolytic AgentsAntimalarialsAnticoagulants

Autor:innen und Institutionen

  • Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London W12 0NN, UK.
  • Department of Haematology, Imperial College Healthcare NHS Trust, London W12 0HS, UK.
  • National Heart and Lung Institute, Imperial College London, London W12 0NN, UK.

ORCID-Profile: Deepa J Arachchillage

Förderung

  • Versus Arthritis
  • Medical Research Council
  • MRC UK
  • Imperial College-Wellcome Trust Institutional Strategic

Zitieren

APA

Arachchillage, D. J., Laffan, M., & Pericleous, C. (2023). Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021331

Vancouver

Arachchillage DJ, Laffan M, Pericleous C. Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021331

BibTeX
@article{Arachchillage2023,
  author = {Arachchillage, Deepa J and Laffan, Mike and Pericleous, Charis},
  title = {Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24021331}
}
Kostenlos starten →